Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Evotec : partners with CEBINA to launch Danube Labs, a partnership to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions

06/14/2021 | 04:11am EDT

Vienna, Austria, 14 June 2021:
CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the launch of Danube Labs, a partnership with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) to fast-track early-stage academic research to drug discovery and development. The joint project, financed by a dedicated group of private investors, will identify, and develop academic projects into mature therapeutic product development opportunities, primed for biotech company formation or partnering. Danube Labs aims to create up to 8 new biotech companies over 4 years, and is supported by CEBINA Bridge Capital Limited, a private fund established in Gibraltar and committed to providing a minimum investment of € 10 m.

'We are excited to join forces with Evotec to expand our mission to transform promising research and early-stage drug discovery projects from Central and Eastern Europe into mature projects attractive for forming new companies that will be embedded in the biotech ecosystem CEBINA has created. This partnership brings together great entrepreneurial expertise and experience in drug development that, we believe, will enable us to generate breakthrough therapeutics,' commented Eszter Nagy, MD PhD, founder and CEO&CSO of CEBINA.

'Danube Labs represents the latest of Evotec's BRIDGE partnerships, where we explore exciting academic science with the aim to accelerate the translation of early-stage drug discovery from academia to patients,' commented Mark Slack, PhD, VP Academic Partnerships at Evotec. 'Through our partnership with CEBINA, we see the opportunity to seek out and validate promising innovative research in Central and Eastern Europe'.

For further information on Danube Labs, please follow this link to the full version of CEBINA's press release.

Disclaimer

Evotec SE published this content on 14 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2021 08:10:04 UTC.


ę Publicnow 2021
All news about EVOTEC SE
10:58aEVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
10:58aDGAP-PVR : Evotec SE: Release according to Article 40, Section 1 of the WpHG [th..
DJ
07/06Oxford Cannabinoid Technologies Signs Deal for Phase 1 Trials
DJ
07/02EVOTEC : creates long-term growth opportunities by initiating 'Campus Levi-Monta..
AQ
07/02EVOTEC : Germany's Evotec to Buy GlaxoSmithKline's Italian R&D Facility
MT
07/01EVOTEC : creates long-term growth opportunities by initiating "Campus Levi-Monta..
PU
07/01PRESS RELEASE : Evotec creates long-term growth opportunities by initiating 'Cam..
DJ
07/01EVOTEC : creates long-term growth opportunities by initiating 'Campus Levi-Monta..
EQ
07/01Evotec SE acquired Campus Levi-Montalcini from GlaxoSmithKline plc.
CI
06/30EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
More news
Financials
Sales 2021 561 M 662 M 662 M
Net income 2021 47,3 M 55,8 M 55,8 M
Net Debt 2021 73,5 M 86,8 M 86,8 M
P/E ratio 2021 119x
Yield 2021 -
Capitalization 5 758 M 6 800 M 6 798 M
EV / Sales 2021 10,4x
EV / Sales 2022 9,16x
Nbr of Employees 3 735
Free-Float 84,1%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 35,18 €
Average target price 36,71 €
Spread / Average Target 4,35%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Iris L÷w-Friedrich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE16.18%7 377
MODERNA, INC.233.90%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.39.02%47 022
CELLTRION, INC.-26.46%32 170
SEAGEN INC.-16.87%28 525